Logo image
Sign in
Time Course Of Adverse Events In Primary Advanced Or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy In The ENGOT-EN-6-NSGO/GOG-3031/RUBY Trial
Journal article   Peer reviewed

Time Course Of Adverse Events In Primary Advanced Or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy In The ENGOT-EN-6-NSGO/GOG-3031/RUBY Trial

Elizabeth Lokich, Trine Lembrecht Jørgensen, Destin Black, David Cibula, Lucy Gilbert, Antonella Savarese, Matthew A. Powell, Rebecca Herbertson, Sarah E. Gill, Bradley J. Monk, …
International journal of gynecological cancer, Vol.35(2), p.101722
02/2025

Metrics

2 Record Views

Details

Logo image